Latest News Archive

Please select Category, Year, and then Month to display items

Break the cycle of road accidents at traffic circles

03 February 2020 | Story Cobus van Jaarsveld | Photo Charl Devenish

Traffic Circle on the UFS Bloemfontein Campus — The Department of Protection Services shares how to #BSafe at traffic circles.

For the majority of drivers, one of the most confusing driving laws is the correct use of a traffic circle, especially in Bloemfontein with the large number of smaller traffic circles constructed over the past few years; also across the University of the Free State (UFS) Bloemfontein Campus.

“In fact, many motorists do not know that there is a difference between a larger traffic circle and a mini traffic circle, other than their size. Can you really be frustrated if someone cuts you off at a traffic circle if you don't know the rules? Arrive Alive has shed some light on the issue,” said Cobus van Jaarsveld, Assistant Director: Threat Detection, Investigations and Liaison in the UFS Department of Protection Services.

What is the difference between the two circles?

A traffic circle is classified as large when it has a minimum diameter of about 16 metres and a 1,5 to 2 metre flattened kerb, which allows heavy vehicles to drive onto a small section of the circle. A mini traffic circle is normally not more than seven to ten metres in diameter and the entire circle is mountable for heavy vehicles.

Are there different rules for each?

Yes – the rule of thumb is that mini traffic circles, which are usually found in residential areas, have the same rules as a four-way stop – first come first served. For larger traffic circles, which are usually found at busy crossings to assist with the traffic flow, you must give way to the right.

Rules to remember at a large traffic circle

As you arrive at a large traffic circle, traffic coming from your right has right of way, regardless of how many cars there are. Wait until there is a gap in the traffic and then ease slowly into the circle. Watch out for other traffic in the circle and be aware that they may not be using their indicators.

Use your indicators

Signal when you are going to turn – switch your indicator on immediately after passing the exit prior to the one you intend taking. If you are taking the first exit, i.e. you're turning left, then flick on your left indicator and keep in the outside/left-hand lane. Keeping in the outside/left-hand lane also works well if you're continuing straight ahead, as your exit is very close. After you've passed the left-turn exit and yours is next, signal left and you're free. If you're turning right or performing a U-turn, keep in the inside/right-hand lane. Only signal left and change into the left-hand lane once you've passed the other exits and only yours is ahead.

Rules to remember at a mini traffic circle

The first vehicle to cross the line has the right of way, so it really works on the same principle as a four-way stop or yield sign. Proceed in a clockwise direction around the circle, without driving on it.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept